Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia
Condition: B-Cell Lymphoblastic Leukemia · Sponsor: Shanghai Jiao Tong University School of Medicine
About this study
The goal of this clinical trial is to evaluate the efficacy of Blinatumomab in pediatric patient with newly diagnosed acute B-Lymphoblastic leukemia with poor response to early chemotherapy, i.e. day 19 MRD ≥ 0.1% (low-risk) or day 19 MRD ≥ 0.01% (intermediate-risk). The main question is: • If the flow cytometric MRD negative (\<0.01%) rate and the NGS- MRD negative (\<0.0001%) rate at the end of induction for patients received Blinatumomab will be superior to historical control (D46MRD in the CCCG-ALL2020 protocol). Participants will: * Take 14 days full dose Blinatumomab; * With bone marrow evaluated before and after Blinatumomab treatment.
This description comes directly from the study's public registry record.
Talk to the study team
Shuhong Shen, PhD/MD · 86-18930830638 · shenshuhong@scmc.com.cn
Wenting Hu, MD · 13524836748 · huwenting@scmc.com.cn
Always discuss trial participation with your own doctor first.
Locations (4)
| Anhui Provincial Children's Hospital | Hefei, Anhui, China | Not Yet Recruiting |
| Fujian Children's Hospital | Fuzhou, Fujian, China | Not Yet Recruiting |
| Shanghai Children's Medical center | Shanghai, Shanghai Municipality, China | Recruiting |
| Ningbo Women and Children's Hospital | Ningbo, Zhejiang, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06607419